DNA Vaccine Protects Against Toxic Proteins Linked to Alzheimer’s
A new DNA vaccine when delivered to the skin prompts an immune response that produces antibodies to protect against toxic proteins associated with Alzheimer’s disease – without triggering severe brain swelling that earlier antibody treatments caused in some patients. Two studies from the Peter O’Donnell Jr. Brain Institute demonstrate in animals how a vaccine containing DNA of the toxic beta-amyloid protein elicits a different immune response that may be safe for humans. The vaccine, which will likely be tested further by the U.S. Food and Drug Administration (FDA), is on a shortlist of promising antibody treatments that may eventually help settle a high-stakes debate of whether amyloid is a vital target for preventing or curing Alzheimer’s.
Click here to read more.
71st Annual Meeting of the Southern Neurosurgical Society
Feb. 26-29, 2020; Richmond, Va.
3rd Annual Mayo Clinic Advances and Innovations in Complex Neuroscience Patient Care: Brain and Spine 2020
Feb. 27-29, 2020; Sedona, Ariz.
Multidisciplinary Neuro-Oncology Symposium: Updates in Medical and Surgical Management of Brain Tumors
March 6-7, 2020; Orlando, Fla.
5th Annual Safety in Spine Surgery Summit
March 12-13, 2020; New York
EANS Research Course & Young Neurosurgeons Meeting
March 26-28, 2020; Zurich